Among patients with moderate or severe COPD who do not have an established indication for beta-blocker use, the time to first COPD exacerbation is similar in patients receiving metoprolol compared with those receiving placebo.
In a large observational COPD cohort, researchers found a significant percentage of patients with suspicious echocardiographic findings who did not have a diagnosis or receive therapy for cardiovascular disease, indicating an increased risk for an unfavorable prognosis.
For patients with chronic obstructive pulmonary disease (COPD), inhaled corticosteroid (ICS) use was associated with an increased risk of pneumonia, according to the results of a recently published meta-analysis.
Researchers assessed whether a hospital-initiated program that combined transition and long-term self-management support for patients hospitalized because of COPD and their family caregivers could result in improved outcomes.
Measures of reversibility are of limited value for distinguishing smoke-related chronic obstructive pulmonary disease from asthma, but bronchodilator response testing may be a phenotypic marker for asthma.
The board of directors of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recently published an editorial urging more serious action should be taken to better manage chronic obstructive pulmonary disease.
Patients with COPD who have the most severe airflow obstructions according to the GOLD strategy document had more exacerbations than those with less severe obstructions, and were more likely to be treated with both systemic corticosteroids and antibiotics.